

Curriculum Vitae Prof Marie-Odile KREBS, MD, PhD

Full Professor in Psychiatry, University Paris Descartes, Paris

Staff psychiatrist –Sainte-Anne Hospital, Paris

Head of clinical department Service Hospitalo-Universitaire – S14, Centre Hospitalier Sainte-Anne

Team leader “Pathophysiology of psychiatric disorders” Centre de psychiatrie et Neurosciences, U9894, INSERM University Paris Descartes

Coordination of ‘Groupe de recherche en psychiatrie’ GDR 3557 – Institut de Psychiatrie (www.institutdepsychiatrie.org)

Education & Training

- 1994 Qualification as Director of Research (Habilitation à diriger les Recherches, HDR), Univ Paris 5, ‘New pathophysiological models for schizophrenia’ with highest honor (Mention très honorable avec félicitations).
- 1992 PhD in Molecular and cellular pharmacology, option Neurobiology, Univ Paris 6, France, ‘Glutamatergic regulation of dopamine release in the striosomal and matrix compartments of the rat striatum’, under the supervision of Pr J . Glowinski, Collège de France with the highest honor (Mention très honorable avec félicitations)
- 1991-1994 Head Residency – Associate professor (Chef de Clinique - Assistant) Paris
- 1991 Qualification in Psychiatry, Univ Paris 6, France, ‘Phencyclidine-induced psychosis : a model for glutamatergic hypothesis of schizophrenia’ with the highest honor (mention Très Bien)
- 1990 Master in Informatics, Statistics and Epidemiology (Paris XI)
- 1990 MD, Univ Paris 6 – ‘Glutamatergic systems and neuropsychiatric diseases’ with the highest honor (Médaille d’Argent)
- 1988 Master 2 Cellular and Molecular Neuropharmacology, option Neurobiology (Univ Paris 6, mention Très Bien)
- 1985-91 Residency in Psychiatry, Paris

Awards

2014 Grand Prix de l’Académie des Sciences – Fondation Philippe et Maria Halphen 2014

2012 National competition for First class professor (PUPH1C)

2012 Scientific Excellence grant for French Ministry of Education and Scientific Research (2012-2016)

2007 Prime Encadrement De la Recherche (PEDR - 2007-2010)

2005 National competition for tenured professor (PUPH2C)

2005 INSERM National Competition for Tenured Director of Research Position, DR2.

1995 INSERM National Competition for Tenured Research Position, CR1:

1991 Laureate of the Faculty of Medicine, University Paris 6 (1991)

1991 Silver Medal for residency, Faculty of Medicine, University Paris 6 (1991)

1987-1989 Fellowship from Fondation pour la Recherche Médicale as PhD student at College de France

1985- National competition for Residency in Psychiatry (ranked 5th)

Responsibilities

- Since 2011: Head of the University Department of Adult Psychiatry (Service Hospitalo Universitaire de Thérapeutique et Santé Mentale - S14, included in the “Pole 15è” – Head : Pr R Gaillard) – This department has a double orientation : (1) expert – 3d line facility for specialized out patients and in patients clinics focused on early diagnosis and early intervention in psychosis, resistant depression and psychosis, innovative therapy including cognitive training and stimulation therapy (transcranial magnetic stimulation, electro convulsive therapy, deep brain stimulation). (2) first and second line psychiatry associated with a specific catchment area (secteur 14 – 15è arrondissement) for long term follow up of patients with psychosis, bipolar disorders, schizophrenia, dual diagnosis, aging)
- Since 2011 : Coordination of the Clinical Research Center
- Since 2007 : Elected President of Clinical Research Committee in Hôpital Sainte-Anne
- Since 2001 : Head of Inserm Research Team ‘pathophysiology of psychiatric diseases’ EMI 0117; U796; U894

Coordination of research consortium :

- Since 2012 : President of ‘Institut de psychiatrie’, a non profit association based on the ‘Groupe de recherche en psychiatrie’ GDR 3557 www.institutdepsychiatrie.org. This National consortium that comprised 25 research teams affiliated to University or research organizations (CNRS, Inserm, CEA, Inria) and additional clinical teams, biotech SME, (www.institutdepsychiatrie.org) involved in psychiatry, cognition, genetics, brain imaging and data analysis. This consortium aims to foster collaborative projects and organizes scientific animation and training.

- Coordination of Transition network (réseau de Recherche en Soins et en Santé des Populations, (24 centres)
- Coordination of ERANET – Neuron - project AUSZ : From autism to schizophrenia (consortium still ongoing)

Awarded grants : 28 grants from Public, Academic sources and Charities (selection listed below) + 18 fellowships for doctorants and post-doctorants

- 2015 FRM grant DPP20151033966) Personalized approach of biological basis of schizophrenia using neuron-like cells derived from genetically defined patient's blood monocytes
- 2014 PHRC START: Stress in at risk mental state: a controlled randomized study of efficacy of CBT
- 2013-17: ANR Cerbais The adhesion-GPCR BAI3 and its signaling pathway in schizophrenia: from mice models to patients. Coord F Selimi, College de France, coPI G Le Pen
- 2011-2015: Investissement D'avenir-Brainomics – Methodological and software solutions for the integration of neuroimaging and genomic data (Coordinator V Frouin CEA) Brainomics 2003-French Ministry of Health MiRE/DRESS- « *Pathway to care in subjects with high risk of psychosis* »
- 2010-2015: Fond France-Continuum Autisme – Schizophrénie – marqueurs cliniques AUSZ
- 2010-2015 ERANET-Neuron-From Autism to schizophrenia : Study of the genetic mechanisms underlying brain dysfunction and structural phenotypes in schizophrenia and autistic spectrum disorders AUSZ-EUCan
- 2008-ANR EPINEP P007229-Epigénétique, neurite et psychose EPINEP
- 2007-PHRC AOM 07 118-Influence of cannabis psychopathological outcome in At risk mental state ICAAR
- 2007-PICRI -Influence of prenatal exposure to artificial hormones on vulnerability to psychiatric disorders. Collaboration with user's organization Hhorrages
- 2007-Fond Wyeth -Cannabis : peut on prédire les risques ? VULCAN
- 2006-Réseau INSERM-„Transition“ Multicentric network on psychosis onset.
- 2004-MGEN Inserm-« *Early detection and prevention in subjects with high risk of psychosis* »

Special achievements in research

- Regulation of dopamine release through presynaptic NMDA receptors in the striatum
- Heterogeneity of glutamatergic regulation of DA release in striosomal and matrix compartment of the rat striatum
- Characterization and refining the definition of developmental forms of schizophrenia, in relation with neurological dysfunction and brain morphological deviance
- Validation a new animal model for schizophrenia in rat based on subtle and transient alterations in neurogenesis
- Exploring the influence of substance use in psychosis / schizophrenia and identification of cannabis hypersensitivity
- Identification of point mutations associated with schizophrenia
- Identification of peripheral biomarkers predictive of psychosis transition

Teaching

- Coordination of University Diploma 'Early detection early intervention in young adults (since 2014)
- Coordination of Neuropsychopharmacology teaching (Master de Neurosciences Paris 5, from 2006, now with G Le Pen)
- Master in Neurobiology (Paris 6), European Master in Genetics (Paris 7), Addictology, Master in Neuropsychology and clinical Neurosciences (Univ Lyon 2)
- In Medical School (Paris Descartes)

Supervision and co supervision of 20 PhD and 24 Master of sciences

2018 : C Alexandre, co supervision, in progress); 2017 G Martinez (co supervision); 2016 B Chaumette; 2016 O Gay (co supervision, A Cachia); 2011 F Mouaffak (co supervision); 2011 E Magaud; 2011 O Kebir; 2011 J Tarabeux, (co-supervision with G Rouleau) ; 2010 H Picard (co supervision) ; 2010 A. Dervaux; 2008 S. Mouchet; 2007, F Hazane; 2007 ML Grillon; 2006 A Ouali co-supervision (Levy); 2006 R Gourevitch; 2006 C. Hoareau; 2006 ; 2005 D. Gourion; 2005 C Goldberger; 2003 2004 Z. Ramdane-Chérif; C Daban (co supervision MF Poirier).

Publications and dissemination activities

Publication records (source Web of Sciences, Sept 2017) : **h-index** : 40

Results found: 240 articles or reviews - Sum of the Times Cited : 6235 – (without self-citations : 5894)

Citing Articles: 5220 - (without self-citations : 5089) Average Citations per Item: 25.98

Patent

EP 13 306 428.7 17.10.2013 : Method for in vitro differentiation of blood circulating cells into neuronal-like cells and applications thereof, Hosmalin, A., Feuillet, V., Krebs, M.O., Jay, T., Bellon, A
Patent under review: Methylomic and transcriptomic changes during conversion. Krebs MO , Chaumette B, Kebir O

Selection of 10 publications

1. Kebir O*, Chaumette B*, Rivollier F, Miozzo F, Lemieux Perreault LP, Barhdadi A, Provost S, Plaze M, Bourgin J, the ICAAR team, Gaillard R, Mezger V, Dube MP, Krebs MO : Methylomic changes during conversion to psychosis Mol Psychiatry, 2017 22:512-518.
2. Millan MJ, Andrieux A, Bartzokis G, Cadenhead K, Dazzan P, Fusar-Poli P, Gallinat J, Giedd J, Grayson D, Heinrichs M, Kahn R, Krebs MO, Leboyer M, Lewis D, Marin O, Marin P, Meyer-Lindenberg A, McGorry P, McGuire P, Owen MJ, Patterson P, Sawa A, Spedding M, Uhlhaas P, Vaccarino F, Wahlestedt C and Weinberger D : Altering the course of schizophrenia: progress and perspectives, Nat Rev Drug Disc, 2016 Jul;15(7):485-515.
3. Girard S, Gauthier J, Noreau N, Xiong L, Zhou S, Jouan L, Dionne-Laporte A, Spiegelman D, Henrion E, Diallo O, Thibodeau P, Bachand I, Bao JYJ, Tong AMY, Lin CH, Millet B, Jaafari N, Joobor R, Dion PA, Lok Si, Krebs MO*, Rouleau GA* (lasT coauthor) Increased exonic de novo mutation rate in individuals with schizophrenia. Nat Genet. 2011 Jul 10;43(9):860-3
4. Gauthier J, Champagne N, Lafrenière RG, Xiong L, Spiegelman D, Brustein E, Lapointe M, Peng H, Côté M, Noreau A, Hamdan FF, Addington AM, Rapoport JL, Delisi LE, Krebs MO, Joobor R, Fathalli F, Mouaffak F, Haghghi AP, Néri C, Dubé MP, Samuels ME, Marineau C, Stone EA, Awadalla P, Barker PA, Carbonetto S, Drapeau P, Rouleau GA; S2D Team. De novo mutations in the gene encoding the synaptic scaffolding protein SHANK3 in patients ascertained for schizophrenia. Proc Natl Acad Sci U S A. 2010 Apr 27;107(17):7863-8.
5. Tarabeux J, Champagne N, Brustein E, Hamdan FF, Julie Gauthier J , Lapointe M, Maios c, Piton A, Spiegelman D, Henrion E, S2D team, Millet B, Rapoport JL, DeLisi LE, Joobor R, Fathalli F, Fombonne E, Motttron L, Forget-Dubois N, Boivin M, Michaud JL, Lafrenière RG, Drapeau P, Krebs MO, Rouleau GA. : De Novo Truncating Mutation in KIF17 Associated with Schizophrenia, Biol Psychiatry 2010, Oct 1;68(7):649-56.
6. Matricon J, Bellon A, Frieling H, Kebir O, Le Pen G, Beuvon F, Daumas-Duport C, Jay TM, Krebs MO. 2010. Neuropathological and Reelin Deficiencies in the Hippocampal Formation of Rats Exposed to MAM; Differences and Similarities with Schizophrenia. PLoS One. 2010 Apr 22;5(4):e10291.
7. Krebs MO, Bellon A, Mainguy G, Jay TM, Frieling H. One-carbon metabolism and schizophrenia: current challenges and future directions. Trends Mol Med. 2009 Dec;15(12):562-70.
8. Picard H, Amado I, Mouchet-Mages S, Olié JP, Krebs MO. The role of the cerebellum in schizophrenia: an update of clinical, cognitive and functional evidence *Schizophrenia Bull* 2008, 34: 155-72 (IF 5,843)
9. Krebs MO, Guillin O., Bourdel MC., Schwartz JC., Olié JP., Poirier MF., Sokoloff P. BDNF gene variants association with age at onset and therapeutic response in schizophrenia. Mol Psychiatry, 2000 , 5, 558-62. (IF : 6,25)
10. Krebs MO, Desce JM, Kemel ML, Gauchy C, Godeheu G, Cheramy A, Glowinski J. Glutamatergic control of dopamine release in the rat striatum: evidence for presynaptic N-methyl-D-aspartate receptors on dopaminergic nerve terminals. J Neurochem. 1991 Jan;56(1):81-5.(332 citations)

Dissemination:

- Regularly interviewed for lay communications (Le Monde 2016, Le Figaro 2017, New York Times, Ça m'intéresse, Science et Avenir, Inrockuptible, Valeurs mutualistes ...), for TV show (Arte, M6, practis TV) or for exhibition (Cité des Sciences de la Villette, lay conference "Carte Blanche" on adolescence 'T'inquiète je gère' 2016). French TV Fr3 Dec 2015; BFM TV janv 2017), France Inter 2016 ...Recent interviews:
- Interaction with user's organisations (UNAFAM, Schizo Oui, France Dépression, Hhorrages): participation to their annual meetings, and collaboration for research projects; user's meeting.
- Interview by decision makers (interviews to Mission parlementaire, Senator A Milon, OPECS, director of health care services DGS) on risk of cannabis, prevention strategy and early intervention in psychosis, mental health, research (recent interview : Sénat 7 fev 2017; CESE sept 2017)

Organized symposium:

- 2015-ongoing : Organisation of a yearly scientific meeting for user's organizations with the support of Fondation Deniker, Inserm, and French Ministry of Health and Mission des usagers de l'Inserm (120 participants)
- 2012-ongoing : Organisation of the yearly scientific meeting of the GDR 3557 / Institut de psychiatrie (70 participants)

- 2007- ongoing : International meeting on Emergent Disorders in Young adult of adolescents (**JIPEJAAD**), annual conference (100-200 participants)
- 2015 co organizer scientific one day workshop "Innovative technologies in Neurosciences" Aviesan
- Schizophrenia International Research Society Congress "Autistic and cognitive traits in the genetic understanding of the continuum in neurodevelopmental disorders and functional psychosis." Firenze, April 2010
- "Updates in Developmental Models for schizophrenia". 1st Society International Schizophrenia Research Venice, 2008.
- "Reelin : From neuroplasticity to neuropsychiatric diseases". Co-chair : B Allinquant; Colloque Société des Neurosciences, Montpellier, France. Mai 2007
- " Stress, neuronal plasticity and psychiatric diseases". T Jay – MO Krebs; 8th World Congress of Biological Psychiatry, Vienna, Austria. 2005.
- " Developmental Neuropsychopharmacology MO Krebs, A Prochiantz, W Wurst, E. Gould, 14è CINP Paris, France, 2004
- " Disorganization in schizophrenia : implications for understanding the disorder and its treatment": D. Weinberger, M-O Krebs, P. Liddle T.E., Goldberg , I. Amado, 14è CINP Paris, France, 2004.

Invited conferences and Communications : 62 invited conference including : (selection, since 2010)

- 2017: Blood-based molecular biomarkers of transition to psychosis- Symposium Prediction of conversion to psychosis – recent developments : Chair: Anita Riecher-Rössler WPA Conference Berlin, 8-12 October 2017
- 2017: Schizophrénies : de la détection précoce au staging – Marqueurs de vulnérabilité précoce, Congrès de 'Encéphale, 20 janv 2017
- 2016: Methyloomic changes during conversion to psychosis wSymposium "Oxidative Stress in Early Psychosis, from mechanisms to interventions" Chair: A Sutterland, Amsterdam, Co-Chair: P Baumann, Lausanne IEPA, Milan, 22 oct 2016
- 2016: Carte Blanche à la Cité des Sciences - Conférence Universcience sur l'adolescence « T'inquiète je gère : Adolescence troublée ou premiers troubles psychiques ? » – en marge de l'exposition Mental Désordre : changez de regard sur les troubles psychiques, (mai 2016 Paris)
- 2016: « Le cerveau adolescent : une fenêtre du vulnérabilité, une opportunité pour la prévention des troubles psychiatriques » Semaine du Cerveau, Marseille, 18 mars 2016
- 2016: Repérage précoce des troubles psychotiques ... chez les jeunes consommateurs ; Jeunes et addictions : les consultations jeunes consommateurs agir ensemble ! Ministère des affaires sociales et de la santé, 7 octobre 2016
- 2016: Journées d'actualités Physiopathologiques de Strasbourg. Emergence psychotique : un trouble métabolique? Strasbourg, 1er décembre 2016.
- 2016: Methyloomic changes during conversion to psychosis invited conference in Symposium "Oxidative Stress in Early Psychosis, from mechanisms to interventions" Chair: Arjen Sutterland, University of Amsterdam, Co-Chair: Philipp Baumann, Lausanne University Hospital (CHUV) IEPA, Milan, 22 oct 2016
- 2016: Intérêt de la recherche de biomarqueurs des pathologies psychiatriques. Colloque UNAFAM « Recherche en psychiatrie : des raisons d'espérer ? ». Paris, 23 juin 2016.
- 2016: Jeunes et cannabis: recherche, prévention et accompagnement : « Usage précoce de Cannabis et santé mentale ». Paris, 11 février 2016, AVIESAN (Agence Nationale pour les sciences de la vie et de la santé).
- 2015 : Journées de Formation ADESM. Penser et construire la prévention : Prévention ciblée de la psychose : quels dispositifs ? Paris, Le 12 novembre 2015.
- 2015: Biomarqueurs de la schizophrénie – Académie de médecine, invitée par le Pr B Bioulac, (27 janvier 2015, Paris)
- 2015: Congrès de psychiatrie et Neurologie de langue Française : Juin 2015, Tours : Signes précoces de schizophrénie : des prodromes à la notion de prevention
- 2015: Traitement préventif de la psychose : concepts et états des lieux Congrès de l'Encéphale, 24 janvier 2015 Paris
- 2014: Maturation cérébrale et Maladies Psychiatriques : une opportunité pour la prévention ? Ecole d'été des Neurosciences, 20 septembre 2014
- 2013 : Rare mutations in N-methyl-D-aspartate glutamate receptors in schizophrenia and autism spectrum disorders Invited conference in S.24: CCNP symposium - NMDA hypofunction in schizophrenia: beyond hypothesis to causes, mechanisms, and treatments , Chairs P Botska, M Salter 26th European College of NeuroPsychopharmacology Congress (ECNP), Barcelona, Spain (5-9 Octobre 2013).
- 2013: Whom to treat, how to identify them before conversion : clinical phenotyping, « soft signs », biological signals ANMI Meeting 11-13 April 2013 St Jean Cap Ferrat
- 2012: Neurodevelopment and psychiatric disorders in adults : a diachronic and multi-level approach. Foundation « Les Treilles » 2012 September 24th-29th "Translational Developmental Neuroscience"

- 2012: Schizophrenia (s) as delayed developmental disorders Neurological and psychiatric diseases : a developmental perspective - 15 mars 2012. Séminaire de la chaire des processus morphogénétiques, A Prochiantz
- 2010: Psychopharmacological treatment of psychotic disorders » IConS IV of SCARF 2010 22-24 octobre Chenai, India
- 2010: « Autistic and cognitive traits in the genetic understanding of the continuum in neurodevelopmental disorders and functional psychosis ». 2nd Schizophrenia International Research Society. Italie, Florence, 10-14 avril 2010.
- 2010: Marqueurs de vulnérabilité et facteurs de risque de psychose . 10^{èmes} Journées de Psychiatrie Biologique sur « les psychoses débutantes ». Tunisie, Sousse, 22-24 avril 2010.
- 2010: Development and schizophrenia“ Conférence ZSN- Zentrum für systemische Neurowissenschaften Hannover. Allemagne, Hannover, 18 novembre 2010.

Books and chapters

- Krebs M.O, Signes Précoces de schizophrénie. Des prodromes à la notion de prévention. Coll Psychothérapie. Dunod **2015**. Participating authors; Alexandre C, Amado I, Bourgin J. Chaumette B, Cuenca M, Daban C, Dadi G, Gay O, Jay Th, Kébir O, Mam-Lam-Fook C, Martinez G, Oppéit A, Plaze M, Rousselet A.V., Lama S. pp 224
- Deroin C, Krebs MO : “Mon frère a un petard dans la tête” [Le cannabis} Oskar Editeur 2016

56 book chapters including : (selection since 2010)

- Olié JP, Lôi H, Gaillard R, Krebs MO. Jean Delay et Pierre Deniker l'esprit de deux fondateurs de la psychiatrie contemporaine. Ouvrage 150 ans CHSA. 2017, Editeur Somogy.66-70
- Henckes, Poirier MF, Krebs MO. Un site pour la recherche. Ouvrage 150 ans CHSA. 2017, Editeur Somogy. 118-123.
- Krebs MO, O Kebir, T Jay. La recherche en biologie : modèles et méthodes. Manuel de Psychiatrie. Ouvrage coordonné par JD Guelfi et F Rouillon. 2^{ème} édition, 2016. Elsevier Masson, 62-69.
- Krebs MO. “Thérapeutiques Biologiques”. Manuel de Psychiatrie. Ouvrage coordonné par JD Guelfi et F Rouillon. 3^{ème} édition, 2016. Elsevier Masson, p 599-670.
- Smyrnis N, Amado I, Krebs MO, Sweeney J Eye movement in schizophrenia in “Eye Movements in Psychiatry” in press
- Gay O and Krebs MO : “Imagerie et schizophrénie” in Apport de la neuro imagerie à la connaissance psychiatrique », P. Fossati (Ed.), Lavoisier, 2015
- Dervaux A, Morvan Y, Laqueille X, Krebs MO. 2015 Les effets néfastes du cannabis, un facteur de risque à l'adolescence? In L'addiction chez les adolescents. Dir N. Battaglia & F. Gierski. Ed De Boeck-Solal : 93-126.
- Gay O and Krebs MO “Aspects neurodéveloppementaux des troubles bipolaires” in Les troubles bipolaires, Ed Bourgeois ML, Gay C, Henry C, Masson M. (Ed) Lavoisier, 2014.
- Krebs MO : Détection précoce dans les psychoses débutantes , 2014 in ‘Dépistage et traitements précoces des premiers épisodes psychotiques: schizophrénie et troubles bipolaires ‘ Ed John Libbey.
- Beck F, Dervaux A, Du Roscoät E, Gallopel-Morvan K, Grall-Bronnec M, Kern L, Krebs MO, Legleye S, Melchior M, Naassila M, Peretti-Watel P, Phan O, Romo L, Spilka S. Expertise collective Inserm Conduites addictives chez les adolescents. Usages, prévention et accompagnement. Chapitre Effets néfastes du cannabis. Ed Inserm 2014: 192-232.
- Dervaux A, Krebs MO, Laqueille X. Addiction au cannabis et troubles psychiatriques. In Addictions et comorbidités. Rapport Congrès de psychiatrie et de neurologie de langue française (CPNLF) Dir A. Benyamina, 2014. Paris, Dunod : 207-22.
- Dadi, G., Morvan, Y., Amado, I., Jay, T., Krebs, MO., Dervaux, A. Usage de Cannabis et Fonctions Cognitives : Manifestations aiguës et à long terme, Influence de l'âge de début de l'usage, In. Les entretiens de Bichat, Paris, 2013.
- Kébir O, Tarabeux J, Krebs MO. «Facteurs génétiques de la schizophrénie » par in « Les schizophrénies » coordonné par Pr Jean DALERY – Lavoisier, (2013)
- De Maricourt P, Krebs MO.(2012) « Les antidépresseurs dans le traitement des schizophrénies », in “Antidépresseurs”, collection Flammarion Médecine-Sciences
- Le Pen G, Bellon A, Krebs M-O, Jay TM (2011). “Gestational MAM (methylazoxymethanol acetate) Administration: A Promising Animal Model for Psychosis Onset”. In O'Donnell P, “Animal models of schizophrenia and related disorders”, Humana Press, pp 25-77.
- Krebs M.O., Bourgin J., Poirier M.F. Neurobiologie de la dépression, in « Les états dépressifs », Médecine Sciences Ed, M Goudemand, Paris, 2010, 344-362.
- Krebs MO Bourgin J Poirier MF : Mécanismes d'action des antidépresseurs in Les états dépressifs , Médecine Sciences Ed Goudemand M. ; Médecines-Sciences Lavoisier, Paris 2010, 395-427.

Publication list**1. Original and review paper in peer reviewed international journals**◆ **2018**

1. Croca M, Lagodka A, Gadel R, Bourdel MC, Bendjemaa N, Gaillard R, Olié JP, Champagne-Lavau M, Krebs MO, Amado I. Theory of mind and schizophrenia in young and middle-aged patients: Influence of executive functions. *Psychiatry Res.* 2018 Jan;259:532-537.

◆ **2017**

2. Caldani S, Amado I, Bendjemaa N, Vialatte F, Mam-Lam-Fook C, Gaillard R, Krebs MO, Pia Bucci M : Oculomotricity and Neurological Soft Signs: Can we refine the endophenotype? A study in subjects belonging to the spectrum of schizophrenia. *Psychiatry Res.* 2017 Oct;256:490-497
3. Parellada M, Pina-Camacho L, Moreno C, Aleman Y, Krebs MO, Desco M, Merchán-Naranjo J, Del Rey-Mejías A, Boada L, Llorente C, Moreno D, Arango C, Janssen J. Insular pathology in young people with high-functioning autism and first-episode psychosis. *Psychol Med.* 2017 Oct;47(14):2472-2482.
4. Teremetz M, Carment L, Brenugat-Herne L, Croca M, Bleton JP, Krebs MO, Maier MA, Amado I, Lindberg PG. Manual dexterity in schizophrenia-a neglected clinical marker? *Frontiers in Psychiatry.* *Front Psychiatry.* 2017 Jul 10;8:120. doi: 10.3389/fpsyt.2017.00120. eCollection 2017.
5. Oppetit A, Brébant C, Monchablon D, Bourgin J, Gaillard R, Olié JP, Krebs MO, Morvan Y. [Early detection of mental health disorders at school: The Fil Harmonie pilot program]. *Encephale.* 2017 Mar 24. pii: S0013-7006(17)30062-3. doi: 10.1016/j.encep.2017.01.006.
6. Zanello M, Pallud J, Baup N, Peeters S, Turak B, Krebs MO, Oppenheim C, Gaillard R, Devaux B. History of psychosurgery at Sainte-Anne Hospital, Paris, France, through translational interactions between psychiatrists and neurosurgeons. *Neurosurg Focus.* 2017 Sep;43(3):E9.
7. Sauvanaud F, Kebir O, Vlasie M, Doste V, Amado I, Krebs MO. Therapeutic benefit of a registered psychoeducation program on treatment adherence, objective and subjective quality of life: French pilot study for schizophrenia. *Encephale.* 2017: 43:235-240
8. Rivollier F, Chaumette B, Bendjemaa N, Chayet M, Millet B, Jaafari N, Barhdadi A, Perreault LPL, Provost S, Dube MP, Gaillard R, Krebs MO, Kebir O (2017). Methylomic changes in individuals with psychosis, prenatally exposed to endocrine disrupting compounds: Lessons from diethylstilbestrol. *Plos One.* 2017 Apr 13;12(4):e0174783. doi: 10.1371/journal.pone.0174783. eCollection 2017.
9. Mam-Lam-Fook C, Danset-Alexandre C, Pedron L, Amado I, Gaillard R, Krebs MO. Neuropsychology of subjects with ultra-high risk (UHR) of psychosis: A critical analysis of the literature. *Encephale.* 2017 May;43(3):241-253. doi: 10.1016/j.encep.2017.02.001. Epub 2017 Mar 25.
10. Martinez G, Alexandre C, Mam-Lam-Fook C, Bendjemaa N, Gaillard R, Garel P, Dziobek I, Amado I, Krebs MO (2017). Phenotypic continuum between autism and schizophrenia: Evidence from the movie for the assessment of social cognition (MASC). *Schizophrenia Research.* 185:161-166
11. **Kebir O* Chaumette B*, Rivollier F, Miozzo F, Lemieux Perreault LP, Barhdadi A, Provost S, Plaze M, Bourgin J, the ICAAR team, Gaillard R, Mezger V, Dube MP, Krebs MO : Methylomic changes during conversion to psychosis *Mol Psychiatry*, 2017 22:512-518.**
12. Charles L, Gaillard R, Amado I, Krebs MO, Bendjemaa N, Dehaene S. Conscious and unconscious performance monitoring: Evidence from patients with schizophrenia. *Neuroimage.* 2017 Jan 1;144(Pt A):153-163.
13. Gay O, Plaze M, Oppenheim C, Gaillard R, Olie JP, Krebs MO, Cachia A (2017). Cognitive control deficit in patients with first-episode schizophrenia is associated with complex deviations of early brain development. *J Psychiatry Neurosci.* 2017 Mar;42(2):87-94.
14. Oppetit A, Bourgin J, Martinez G, Kazes M, Mam-Lam-Fook C, Gaillard R, Olié JP, Krebs MO. The C'JAAD: a French team for early intervention in psychosis in Paris. *Early Interv Psychiatry.* 2016 Sep 28.
15. Oppetit A, Brébant C, Monchablon D, Bourgin J, Gaillard R, Olié JP, Krebs MO, Morvan Y. [Early detection of mental health disorders at school: The Fil Harmonie pilot program]. *Encephale.* 2017 Mar 24. pii: S0013-7006(17)30062-3. doi: 10.1016/j.encep.2017.01.006.
16. Souaiby L, Gauthier C, Rieu C, Krebs MO, Advenier-Iakovlev E, Gaillard R. Clozapine and long-acting injectable antipsychotic combination: A retrospective one-year mirror-image study. *Schizophr Res.* 2017 Jan 27. pii: S0920-9964(17)30049-X. doi: 10.1016/j.

17. Lindberg PG, Térémetz M, Charron S, Kebir O, Saby A, Bendjemaa N, Lion S, Crépon B, Gaillard R, Oppenheim C, Krebs MO, Amado I. Altered cortical processing of motor inhibition in schizophrenia. *Cortex*. 2016 Dec;85:1-12.
18. Caldani S, Bucci MP, Lamy JC, Seassau M, Bendjemaa N, Gadel R, Gaillard R, Krebs MO, Amado I. Saccadic eye movements as markers of schizophrenia spectrum: Exploration in at-risk mental states. *Schizophr Res*. 2017 181:30-37
19. Halayem S, Hammami M, Fakhfakh R, Gaddour N, Tabbane K, Amado I, Krebs MO, Bouden A. [Adaptation and validation of the neurological soft sign's scale of Krebs et al. to children]. *Encephale*. 2017 43:128-134
20. Chaumette B, Kebir O, Krebs MO. [Genetics and epigenetics of schizophrenia and other psychoses]. *Biol Aujourdhui*. 2017;211(1):69-82.

◆ 2016

21. Dunn W Jr, Burgun A, Krebs MO, Rance B. Exploring and visualizing multidimensional data in translational research platforms. *Brief Bioinform*. 2016 Sep 1. pii: bbw080.
22. Dadi G, Dervaux A, Krebs MO, Gaillard R, Laqueille X, Plaze M. Persistent Depersonalization/Derealization Disorder Induced by Synthetic Cannabinoids. *Am J Psychiatry*. 2016 Aug 1;173(8):839-40
23. Amado I, Brénuqat-Herné L, Orriols E, Desombre C, Dos Santos M, Prost Z, Krebs MO, Piolino P. A Serious Game to Improve Cognitive Functions in Schizophrenia: A Pilot Study. *Front Psychiatry*. 2016 Apr 20;7:64.
24. Compère L, Mam-Lam-Fook C, Amado I, Nys M, Lalanne J, Grillon ML, Bendjemaa N, Krebs MO, Piolino P. Self-reference recollection effect and its relation to theory of mind: An investigation in healthy controls and schizophrenia. *Conscious Cogn*. 2016 May;42:51-64.
25. **Millan MJ, Andrieux A, Bartzokis G, Cadenhead K, Dazzan P, Fusar-Poli P, Gallinat J, Giedd J, Grayson D, Heinrichs M, Kahn R, Krebs MO, Leboyer M, Lewis D, Marin O, Marin P, Meyer-Lindenberg A, McGorry P, McGuire P, Owen MJ, Patterson P, Sawa A, Spedding M, Uhlhaas P, Vaccarino F, Wahlestedt C and Weinberger D : Altering the course of schizophrenia: progress and perspectives, *Nat Rev Drug Disc*, 2016 Jul;15(7):485-515.**
26. Bourguou S, Halayem S, Amado I, Triki R, Bourdel MC, Franck N, Krebs MO, Tabbane K, Bouden A. Theory of mind in adolescents with early-onset schizophrenia: correlations with clinical assessment and executive functions. *Acta Neuropsychiatr*. 2016 Aug;28(4):232-8.
27. Soler J, Miret S, Lázaro L, Parellada M, Martín M, Lera-Miguel S, Rosa A, de Castro-Catala M, Cuesta MJ, Fañanas L, Krebs MO, Fatjó-Vilas M. Influence of DAOA and RGS4 genes on the risk for psychotic disorders and their associated executive dysfunctions: A family-based study. *Eur Psychiatry*. 2016 Feb;32:42-7
28. Renard J, Vitalis T, Rame M, Krebs MO, Lenkei Z, Le Pen G, Jay TM. Chronic cannabinoid exposure during adolescence leads to long-term structural and functional changes in the prefrontal cortex. *Eur Neuropsychopharmacol*. 2016 Jan;26(1):55-64.
29. Chaumette B, Kebir O, Mam-Lam-Fook C, Morvan Y, Bourgin J, Godsil B.P, Plaze M, Gaillard R, Jay T. M, Krebs MO. Salivary cortisol in early psychosis: new findings and meta-analysis *Psychoneuroendocrinology* 2016 Oct 16;63:262-270.
30. **Alexandre C, Chaumette B, Martinez G, Christa L, Dupont J.M., Kebir O, Gaillard R, Amado I, Krebs M.O. Paradoxical improvement of schizophrenic symptoms by a dopaminergic agonist : an example of personalized psychiatry in a CNV carrying patient. *Biol Psychiatry*. 2016 Aug 15;80(4):e21-3.**
31. Vinckier F, Gaillard R, Palminteri S, Rigoux L, Salvador A, Fornito A, Adapa R, Krebs MO, Pessiglione M, Fletcher PC. Confidence and psychosis: a neuro-computational account of contingency learning disruption by NMDA blockade. *Mol Psychiatry*. 2016 Jul;21(7):946-55.
32. Souaiby L, Gaillard R, Krebs MO. [Duration of untreated psychosis: A state-of-the-art review and critical analysis]. *Encephale*. 2016 Aug;42(4):361-6.
33. Chaumette B, Kebir O, Mam-Lam-Fook C, Bourgin J, Godsil BP, Gaillard R, Jay TM, Krebs MO – Stress et Transition Psychotique : revue de la littérature - *Encéphale*. 2016 Aug;42(4):367-73.

◆ 2015

34. **Chan MK, Krebs MO, Cox D, Guest PC, Yolken RH, Rahmoune H, Rothermundt M, Steiner J, Leweke FM, van Beveren NJ, Niebuhr DW, Weber NS, Cowan DN, Suarez-Pinilla P, Crespo-Facorro B, Mam-Lam-Fook C, Bourgin J, Wenstrup RJ, Kaldate RR, Cooper JD, Bahn S. Development of a blood-based molecular biomarker test for identification of schizophrenia before disease onset. *Transl Psychiatry*. 2015 Jul 14;5:e601.**
35. Plaze M, Mangin JF, Paillère-Martinot ML, Artiges E, Olié JP, Krebs MO, Gaillard R, Martinot JL, Cachia A. "Who is talking to me?" - Self-other attribution of auditory hallucinations and sulcation of the right temporoparietal junction. *Schizophr Res*. 2015 Oct 10. pii: S0920-9964(15)30011-6. doi: 10.1016/j.schres.2015.10.011 [in press]

36. Kalenzaga S, Sperduti M, Anssens A, Martinelli P, Devauchelle AD, Gallarda T, Delhommeau M, Lion S, Amado I, Krebs MO, Oppenheim C, Piolino P. Episodic memory and self-reference via semantic autobiographical memory: insights from an fMRI study in younger and older adults. *Front Behav Neurosci*. 2015 ;8:449. doi: 10.3389/fnbeh.2014
37. Haro JM, Altamura C, Corral R, Elkis H, Evans J, Malla A, Krebs MO, Zink M, Bernasconi C, Lalonde J, Nordstroem AL. Understanding the impact of persistent symptoms in schizophrenia: Cross-sectional findings from the Pattern study. *Schizophr Res*. 2015 Dec;169(1-3):234-40.
38. Pillet B, Morvan Y, Todd A, Franck N, Duboc C, Grosz A, Launay C, Demily C, Gaillard R, Krebs MO, Amado I. Cognitive remediation therapy (CRT) benefits more to patients with schizophrenia with low initial memory performances. *Disabil Rehabil*. 2015; 37(10):846-53.
39. Girard SL, Dion PA, Bourassa CV, Geoffroy S, Lachance-Touchette P, Barhdadi A, Langlois M, Joober R, Krebs MO, Dubé MP, Rouleau GA. Mutation burden of rare variants in schizophrenia candidate genes. *PLoS One*. 2015 Jun 3;10(6):e0128988. doi: 10.1371/journal.pone.0128988.
40. Richard M, Aimé X, Krebs MO, Charlet J. Enrich classifications in psychiatry with textual data: an ontology for psychiatry including social concepts. *Stud Health Technol Inform*. 2015;210:221-3.
41. Córdova-Palomera A, Fatjó-Vilas M, Gastó C, Navarro V, Krebs MO, Fañanás L. Genome-wide methylation study on depression: differential methylation and variable methylation in monozygotic twins. *Transl Psychiatry*. 2015 Apr 28;5:e557. doi: 10.1038/tp.2015.49.
42. Jaafari N, Chopin N, Levy C, Rotgé JY, Lafay N, Hammi W, Rigalleau F, Millet B, Krebs MO, Vibert N; Insight Study Group. Excessive checking behavior during an image comparison task in schizophrenia. *Eur Psychiatry*. 2015 Feb;30(2):233-41.
43. Córdova-Palomera A, Fatjó-Vilas M, Kebir O, Gastó C, Krebs MO, Fañanás L. Polymorphic variation in the epigenetic gene DNMT3B modulates the environmental impact on cognitive ability: a twin study. *Eur Psychiatry*. 2015 Feb;30(2):303-8.
44. Cachia A, Amad A, Brunelin J, Krebs MO, Plaze M, Thomas P, Jardri R. Deviations in cortex sulcation associated with visual hallucinations in schizophrenia. *Mol Psychiatry*. 2015 Sep;20(9):1101-7.

◆ 2014

45. Krebs MO, Morvan Y, Jay T, Gaillard R, Kebir O. Psychotomimetic effects at initiation of cannabis use are associated with cannabinoid receptor 1 (CNR1) variants in healthy students. *Mol Psychiatry*. 2014 Jan 21. doi: 10.1038/mp.2013.188. (IF 14,897)
46. Kebir O, Chaumette B, Fatjó-Vilas M, Ambalavanan A, Ramoz N, Xiong L, Mouaffak F, Millet B, Jaafari N, DeLisi LE, Levinson D, Joober R, Fañanás L, Rouleau G, Dubertret C, Krebs MO. Family-based association study of common variants, rare mutation study and epistatic interaction detection in HDAC genes in schizophrenia. *Schizophr Res*. 2014 Dec;160(1-3):97-103.
47. Magaud E, Morvan Y, Rampazzo A, Alexandre C, Willard D, Gaillard R, Kazes M, Krebs MO. Subjects at Ultra High Risk for psychosis have 'heterogeneous' intellectual functioning profile: A multiple-case study. *Schizophr Res*. 2014 Feb;152(2-3):415-20.
48. Vinckier F, Cohen L, Oppenheim C, Salvador A, Picard H, Amado I, Krebs MO, Gaillard R. Reading impairment in schizophrenia: Dysconnectivity within the visual system. *Neuropsychologia*. 2014 Jan;53:187-96.
49. Renard J, Krebs MO, Le Pen G, Jay TM. Long-term consequences of adolescent cannabinoid exposure in adult psychopathology. *Front Neurosci*. 2014 Nov 10;8:361.
50. Teremetz M, Amado I, Bendjemaa N, Krebs MO, Lindberg PG, Maier MA. Deficient grip force control in schizophrenia: behavioral and modeling evidence for altered motor inhibition and motor noise. *PLoS One*. 2014 Nov 4;9(11):e111853.
51. Rivollier F, Lotersztajn L, Chaumette B, Krebs MO, Kebir O. [Epigenetics of schizophrenia: a review]. *Encephale*. 2014 Oct;40(5):380-6.
52. Krebs MO, Magaud E, Willard D, Elkhazen C, Chauchot F, Gut A, Morvan Y, Bourdel MC, Kazes M. [Assessment of mental states at risk of psychotic transition: validation of the French version of the CAARMS]. *Encephale*. 2014 Dec;40(6):447-56.
53. Millet B, Jaafari N, Polosan M, Baup N, Giordana B, Haegelen C, Chabardes S, Fontaine D, Devaux B, Yelnik J, Fossati P, Aouizerate B, Krebs MO, Robert G, Jay T, Cornu P, Vérin M, Drapier S, Drapier D, Sauleau P, Peron J, Le Jeune F, Naudet F, Reymann JM. Limbic versus cognitive target for deep brain stimulation in treatment-resistant depression: accumbens more promising than caudate. *Eur Neuropsychopharmacol*. 2014 Aug;24(8):1229-39.
54. European Network of National Networks studying Gene-Environment Interactions in Schizophrenia (EU-GEI), van Os J, et al. Identifying gene-environment interactions in schizophrenia: contemporary challenges for integrated, large-scale investigations. *Schizophr Bull*. 2014 Jul;40(4):729-36.

55. Berna F, Huron C, Kazès M, Offerlin-Meyer I, Willard D, Verry P, Hedélin G, Krebs MO, Danion JM. Chronic persecutory delusion and autobiographical memory in patients with schizophrenia: a diary study. *Isr J Psychiatry Relat Sci*. 2014;51(1):25-33.

◆ **2013**

56. Gay O, Plaze M, Oppenheim C, Mouchet-Mages S, Gaillard R, Olié JP, Krebs MO, Cachia A. Cortex Morphology in First-Episode Psychosis Patients With Neurological Soft Signs. *Schizophrenia Bull* 2013 Jul;39(4):820-9. (IF 8,48)
57. Renard J, Krebs MO, Jay TM, Le Pen G. Long-term cognitive impairments induced by chronic cannabinoid exposure during adolescence in rats: a strain comparison. *Psychopharmacology (Berl)*. 2013 Feb;225(4):781-90
58. Dervaux A, Bourdel MC, Laqueille X, Krebs MO. Neurological soft signs in non-psychotic patients with cannabis dependence. *Addict Biol*. 2013 Mar;18(2):214-21.
59. Sperduti M, Martinelli P, Kalenzaga S, Devauchelle AD, Lion S, Malherbe C, Gallarda T, Amado I, Krebs MO, Oppenheim C, Piolino P. Don't be Too Strict with Yourself! Rigid Negative Self-Representation in Healthy Subjects Mimics the Neurocognitive Profile of Depression for Autobiographical Memory. *Front Behav Neurosci*. 2013 May 21;7:41.
60. Jouan L, Girard SL, Dobrzeniecka S, Ambalavanan A, Krebs MO, Joobor R, Gauthier J, Dion PA, Rouleau GA. Investigation of rare variants in LRP1, KPNA1, ALS2CL and ZNF480 genes in schizophrenia patients reflects genetic heterogeneity of the disease. *Behav Brain Funct*. 2013 Feb 20;9:9.
61. Burbaud P, Clair AH, Langbour N, Fernandez-Vidal S, Goillandeau M, Michelet T, Bardinet E, Chéreau I, Durif F, Polosan M, Chabardès S, Fontaine D, Magnié-Mauro MN, Houeto JL, Bataille B, Millet B, Vérin M, Baup N, Krebs MO, Cornu P, Pelissolo A, Arbus C, Simonetta-Moreau M, Yelnik J, Welter ML, Mallet L; French Stimulation dans le Trouble Obsessionnel Compulsif Study Group. Neuronal activity correlated with checking behaviour in the subthalamic nucleus of patients with obsessive-compulsive disorder. *Brain*. 2013 Jan;136(Pt 1):304-17.
62. Grillon ML, Oppenheim C, Varoquaux G, Charbonneau F, Devauchelle AD, Krebs MO, Baylé F, Thirion B, Huron C. Hyperfrontality and hypoconnectivity during refreshing in schizophrenia. *Psychiatry Res*. 2013 Mar 30;211(3):226-33.
63. Martinelli P, Sperduti M, Devauchelle AD, Kalenzaga S, Gallarda T, Lion S, Delhommeau M, Anssens A, Amado I, Meder JF, Krebs MO, Oppenheim C, Piolino P. Age-related changes in the functional network underlying specific and general autobiographical memory retrieval: a pivotal role for the anterior cingulate cortex. *PLoS One*. 2013 Dec 18;8(12):e82385.
64. Dervaux A, Bourdel MC, Laqueille X, Krebs MO. Neurological soft signs in non-psychotic patients with cannabis dependence. *Addict Biol*. 2013 Mar;18(2):214-21.

◆ **2012**

65. Kebir O, Krebs MO. **Diethylstilbestrol and risk of psychiatric disorders: a critical review and new insights. *World J Biol Psychiatry*. 2012, 13: 84-95, [review] (IF 5.564)**
66. Landgraf S, Amado I, Berthoz A, Van Der Meer E*, Krebs MO*. Cognitive Identity in Schizophrenia: Vision, Space, and Body from Prodrome to Syndrome. *Curr Psych Review*, 2012, (In press) [review].
67. Delavest M, Even C, Benjemaa N, Poirier MF, Jockers R, Krebs MO. Association of the intronic rs2072621 polymorphism of the X-linked GPR50 gene with affective disorder with seasonal pattern. *Eur Psychiatry*. 2012. (IF 3.08) in press
68. Landgraf S, Amado I, Berthoz A, Van Der Meer E*, Krebs MO*. Cognitive Identity in Schizophrenia: Vision, Space, and Body from Prodrome to Syndrome. *Curr Psych Review*, 2012, 8, In press [review].
69. Le Seac'h A, Picard H, Gorsane MA, Vidal PP, Amado I, Krebs MO. A step toward an objective quantification of subtle neurological signs in schizophrenia. *Psychiatry Res*. 2012 Jul 30;198(2):230-4.
70. Picard H, Le Seac'h A, Amado I, Gaillard R, Krebs MO, Beauvillain C : Impaired saccadic adaptation in schizophrenic patients with high neurological soft sign scores. *Psychiatry Res*. 2012 Aug 30;199(1):12-8.

◆ **2011**

71. Amado I, Lupianez J, Chirio M, Landgraf S, Willard D, Olié JP, Krebs MO. Alertness can be improved by an interaction between orienting attention and alerting attention in schizophrenia. *Behavioural and Brain Functions*. 2011, 7:24. (IF 2.336) .
72. Bellon A, Krebs MO, Jay TM. **Factoring Neurotrophins into a Neurite-based Pathophysiological Model of Schizophrenia Progress in Neurobiology. 2011 Apr 14;94(1):77-90. (IF 9.140) [review].**
73. Gauthier J, Siddiqui TJ, Huashan P, Yokomaku D, Hamdan FF, Champagne N, Lapointe M, Spiegelman D, Noreau A, Lafrenière RG, Fathalli F, Joobor R, Krebs MO, DeLisi LE, Mottron L, Fombonne E, Michaud JL, Drapeau P, Carbonetto S, Craig AM, Rouleau GA. Truncating mutations in NRXN2 and NRXN1 in autism spectrum disorders and schizophrenia. *Hum Genet*. 2011 Oct;130(4):563-73 (IF 4.523)
74. Girard S, Gauthier J, Noreau N, Xiong L, Zhou S, Jouan L, Dionne-Laporte A, Spiegelman D, Henrion E, Diallo O, Thibodeau P, Bachand I, Bao JYJ, Tong AMY, Lin CH, Millet B, Jaafari N, Joobor R, Dion PA, Lok Si, Krebs MO, Rouleau GA. Increased exonic de novo mutation rate in individuals with schizophrenia. *Nat Genet*. 2011 Jul 10;43(9):860-3.

75. Hamdan FF, Daoud H, Piton A, Gauthier J, Dobrzyniecka S, Krebs MO, Joober R, Lacaille JC, Nadeau A, Milunsky JM, Wang Z, Carmant L, Mottron L, Beauchamp MH, Rouleau GA, Michaud JL. De Novo SYNGAP1 Mutations in Nonsyndromic Intellectual Disability and Autism. *Biol Psychiatry*. 2011 May 1;69(9):898-901.. (IF 8.926)
76. Jaafari N, Baup N, Bourdel MC, Olié JP, Rotge JY, Wassouf I, Sharov I, Millet B, Krebs MO. Neurological Soft Signs in OCD patients with early age at onset compared with patients with schizophrenia and healthy subjects. *J Neuropsych Clin Neurosciences* 2011 Fall;23(4):409-16.. (IF 2.336)
77. Johnson I, Tabbane K, Dellagi L, Kebir O . Self-Perceived Cognitive Functioning Does Not Correlate With Objective Measures Of Cognition In Schizophrenia. *Comprehensive Psychiatr*2011 Nov-Dec;52(6):688-92.
78. Kebir O, Gorsane MA, Blecha L, Krebs MO, Reynaud M, Benyamina A. Association of Inflammation Genes with Alcohol Dependence/Abuse: A Systematic Review and a Meta-Analysis. *Eur Addict Res*. 2011 Mar 29;17(3):146-153. (IF 1.23) [review].
79. Kebir O, Krebs MO. Diethylstilbestrol and risk of psychiatric disorders : a critical review and new insights. *World J Biol Psychiatry*. 2011 Mar 23. (IF 5.564) [review].
80. Landgraf S, Amado I, Brucks M, Krueger F, Krebs MO, van der Meer E. Inflexible information acquisition strategies mediate visuo-spatial reasoning in stabilized schizophrenia patients. *World J Biol Psychiatry*. 2011 Dec;12(8):608-19 (IF 5.564)
81. Le Pen G, Jay TM and Krebs MO: Effect of antipsychotics on spontaneous hyperactivity and hypersensitivity to mk-801-induced hyperactivity in rats prenatally exposed to methylazoxymethanol. *J Psychopharmacol*. 2011 Jun;25(6):822-35. (IF 3.647)
82. Malloy-Diniz LF, Neves FS, de Moraes PH, De Marco LA, Romano-Silva MA, Krebs MO, Corrêa H. The 5-HTTLPR polymorphism, impulsivity and suicide behavior in euthymic bipolar patients. *J Affect Disord*. 2011 Sep;133(1-2):221-6. (IF 3.763)
83. Morvan Y, Tibaoui F, Bourdel MC, Lôo H, Akiskal KK, Akiskal HS, Krebs MO. Confirmation of the factorial structure of temperamental autoquestionnaire TEMPS-A in non-clinical young adults and relation to current state of anxiety, depression and to schizotypal traits. *J Affect Disord*. 2011 Jun;131(1-3):37-44 (IF 3.763)
84. Mouaffak F, Kebir O, Bellon A, Gourevitch R, Tordjman S, Viala A, Millet B, Jaafari N, Olié JP, Krebs MO. Association of an Uncoupling Protein 4 (UCP4 -SLC25A27) Haplotype with Ultra-resistant schizophrenia. *Pharmacogenomics*, 2011 Feb ; 12 (2) : 185-93. (IF 3, 893)
85. Mouaffak F, Kebir O, Chayet M, Tordjman S, Vacheron MN, Millet B, Jaafari N, Bellon A, Olié JP, Krebs MO. Association of Disrupted in Schizophrenia 1 (DISC 1) Missense Variants with Ultra-Resistant Schizophrenia. *Pharmacogenomics J*. 2011 Aug;11(4):267-73.
86. Mouaffak F, Kebir O, Picard V, Bonhomme-Faivre L, Millet B, Olié JP, Reynaud M, Krebs MO, Benyamina A. Ultra-resistant schizophrenia is not associated with the multidrug-resistant transporter 1 (MDR1) gene rs1045642 variant. *J Clin Psychopharmacol*. 2011 Apr;31(2):236-8.. (IF 5.092)
87. Mouchet-Mages S, Rodrigo S, Cachia A, Mouaffak F, Olie JP, Meder JF, Oppenheim C*, Krebs MO*1. Correlations of cerebello-Thalamo-Prefrontal Structure and neurological soft signs in patients with first episode psychosis. *Acta Psychiatrica Scand*. Jan 2011;451-458. (IF 3.733)
88. Neves FS, Malloy-Diniz L, Romano-Silva MA, Campos SB, Miranda DM, De Marco L, Figueira PG, Krebs MO, Correa H. The role of BDNF genetic polymorphisms in bipolar disorder with psychiatric comorbidities. *J Affect Disord*. 2011 Jun;131(1-3):307-11.. (IF 3.763)
89. Piton A, Gauthier J, Hamdan FF, Lafrenière RG, Yang Y, Henrion E, Laurent S, Noreau A, Thibodeau P, Karemera L, Spiegelman D, Kuku F, Duguay J, Destroismaisons L, Jolivet P, Côté M, Lachapelle K, Diallo O, Raymond A, Marineau C, Champagne N, Xiong L, Gaspar C, Rivière JB, Tarabeux J, Cossette P, Krebs MO, Rapoport JL, Addington A, Delisi LE, Mottron L, Joober R, Fombonne E, Drapeau P, Rouleau GA. Systematic resequencing of X-chromosome synaptic genes in autism spectrum disorder and schizophrenia. *Mol Psychiatry*. 2011 Aug;16(8):867-80.
90. Sila Neves F, Malloy-Diniz L, Romano- Silva MA, Becho Campos S, Marques Miranda D, De Marco L, Gomes Figueira P, Krebs MO, Correa H. The role of BDNF genetic polymorphisms in bipolar disorder with psychiatric comorbidities. . *J Affect Disord*. 2011 131 : 307-311. (IF 3.763)
91. Tarabeux J, Kebir O, Gauthier J, Hamdan F F, Xiong L, Piton A, Spiegelman D, Henrion É, Millet B, S2D team, Fathalli F, Joober R, Rapoport J L, DeLisi L E, Fombonne É, Mottron L, Forget-Dubois N, Boivin M, Michaud J L, Drapeau P, Lafrenière R G, Rouleau G A and Krebs M-O. Rare mutations in N-methyl-D-aspartate glutamate receptors in autism spectrum disorders and schizophrenia. *Transl Psychiatry* 1: e55; doi:10.1038/tp.2011.52

◆ **2010**

92. Awadalla P, Gauthier J, Myers RA, Casals F, Hamdan FF, Griffing AR, Côté M, Henrion E, Spiegelman D, Tarabeux J, Piton A, Yang Y, Boyko A, Bustamante C, Xiong L, Rapoport JL, Addington AM, Delisi JL, Krebs MO, Joober R, Millet B, Fombonne E, Mottron L, Zilvermit M, Keebler J, Daoud H, Marineau C, Roy-Gagnon MH, Dubé MP, Eyre-Walker A, Drapeau P, Stone EA, Lafrenière RG, Rouleau GA. Direct Measure of the De Novo Mutation Rate in Autism and Schizophrenia Cohorts. *Am J Hum Genet*. 2010 Sep 10;87(3):316-24.

* Equal contribution

93. Benyamina A, Kebir O, Blecha L, Reynaud M, Krebs M.O. CNR1 gene polymorphisms in addictive disorders : a systematic review and a meta-analysis *Addiction Biology*. 2010 16: 1-6. Feb 26.
94. Chirio M, Krebs MO, Waismann R, Vanelle JM, Olié JP, Amado I. Attention and visual orienting in siblings, schizophrenic patients, and controls: impairment in attentional disengagement. *J Clin Exp Neuropsychol*. 2010 Jun;32(5):449-54.
95. Dervaux A, Goldberger C, Gourion D, Bourdel MC, Laqueille X, Lôo H, Olié JP, Krebs MO. Impulsivity and sensation seeking in cannabis abusing patients with schizophrenia. *Schizophr Res*. 2010 Nov;123(2-3):278-80.
96. **Gauthier J, Champagne N, Lafrenière RG, Xiong L, Spiegelman D, Brustein E, Lapointe M, Peng H, Côté M, Noreau A, Hamdan FF, Addington AM, Rapoport JL, Delisi LE, Krebs MO, Joober R, Fathalli F, Mouaffak F, Haghghi AP, Néri C, Dubé MP, Samuels ME, Marineau C, Stone EA, Awadalla P, Barker PA, Carbonetto S, Drapeau P, Rouleau GA; S2D Team.** De novo mutations in the gene encoding the synaptic scaffolding protein SHANK3 in patients ascertained for schizophrenia. *Proc Natl Acad Sci U S A*. 2010 Apr 27;107(17):7863-8.
97. Goldberger C, Dervaux A*, Gourion D, Bourdel MC, Lôo H, Laqueille X, Krebs MO : Variable individual sensitivity to cannabis among patients with schizophrenia *Int J Neuropsychopharmacol, Int J Neuropsychopharmacol*. 2010 Oct;13(9):1145-54.
98. Grillon ML, Krebs MO, Gourevitch R, Giersch A, Huron C. Episodic memory and impairment of an early encoding process in schizophrenia. *Neuropsychology*. 2010 Jan;24(1):101-8.(IF = 3,201).
99. Hamdan FF, Daoud H, Rochefort D, Piton A, Gauthier J, Langlois M, Foomani G, Dobrzeniecka S, Krebs M-O, Joober R, Lafrenière RG, Lacaille J-C, Mottron L, Drapeau P, Beauchamp MH, Phillips MS, Fombonne E, Rouleau GA and Michaud JL.(2010) De novo mutations in FOXP1 in cases with intellectual disability, autism, and language impairment. *Am J Hum Genet*. 2010 Nov 12;87(5):671-8.
100. Krebs MO, Bourdel MC, Ramdane-Cherif Z, Bouhours P, Lôo H, Poirier MF, Amado I. Deficit of inhibition motor control in untreated patients with schizophrenia: Further support from visually guided saccade paradigms. *Psychiatry Res*. 2010 Oct 30;179(3):279-84.
101. Landgraf S, Krebs MO, Olié JP, Committeri G, van der Meer E, Berthoz A, Amado I. Real world referencing and schizophrenia: Are we experiencing the same reality? *Neuropsychologia*. 2010 Aug;48(10):2922-30.
102. Le Jeune F, Verin M, N'Diaye K, Drapier D, Leray E, Tezenas S, Baup N, Pelissolo A, Polosan M, Mallet L, Yelnik J, Devaux B, Fontaine D, Chereau I, Bourguignon A, Peron J, Sauleau P, Raoul S, Garin E, Krebs M.O, Jaafari N, Millet B. Decrease of prefrontal metabolism after subthalamic stimulation in obsessive compulsive disorder : a PET study. *Biol Psychiatry*. 2010 Dec 1;68(11):1016-22
103. Magaud E, Kebir O, Gut A, Willard D, Chauchot F, Olie JP, Kazes M, Krebs MO : Altered semantic but not phonological verbal fluency in young help-seeking individuals with Ultra High Risk of psychosis. 2010, *Schizophrenia Res* , 123 : 53-58.
104. Matricon J, Bellon A, Frieling H, Kebir O, Le Pen G, Beuvon F, Daumas-Duport C, Jay TM, Krebs MO. 2010. Neuropathological and Reelin Deficiencies in the Hippocampal Formation of Rats Exposed to MAM; Differences and Similarities with Schizophrenia. *PLoS One*. 2010 Apr 22;5(4):e10291.
105. Mechri A, Gassab L, Slama H, Gaha L, Saoud M, Krebs MO. Neurological soft signs and schizotypal dimensions in unaffected siblings of patients with schizophrenia. *Psychiatry Res*. 2010 Jan 30;175(1-2):22-26.
106. **Tarabeux J, Champagne N, Brustein E, Hamdan FF, Julie Gauthier J , Lapointe M, Maios c, Piton A, Spiegelman D, Henrion E, S2D team, Millet B, Rapoport JL, DeLisi LE, Joober R, Fathalli F, Fombonne E, Mottron L, Forget-Dubois N, Boivin M, Michaud JL, Lafrenière RG, Drapeau P, Krebs MO, Rouleau GA. : De Novo Truncating Mutation in KIF17 Associated with Schizophrenia, Biol Psychiatry 2010, Oct 1;68(7):649-56.**
107. Schroeder M, Krebs MO, Bleich S, Frieling H. Epigenetics and depression: current challenges and new therapeutic options. *Curr Opin Psychiatry*. 2010 Nov;23(6):588-92.
- ◆ **2009**
108. Amado I, Bourdel MC, Daban C, Poirier MF, Loo H, Bouhours P, Krebs MO. Preattentive processes and disorganization in schizophrenia: Influence of a 6-week risperidone treatment. *Prog Neuropsychopharmacol Biol Psychiatry*. 2009 33:1107-1112.
109. Artiges E, Ricalens E, Berthoz S, Krebs MO, Penttilä J, Trichard C, Martinot JL. Exposure to smoking cues during an emotion recognition task can modulate limbic fMRI activation in cigarette smokers. *Addict Biol*. 2009 Sep;14(4):469-77. IF = 4,953.
110. Bellon A, Le Pen G, Matricon J, Jay T, Krebs MO Potential application as screening and drug designing tools of cytoarchitectural deficiencies present in three animal models of schizophrenia. *Exp Op Drug Discov*, 2009; 4 (3) : 257-278, IF = 4.205
111. Hamdan F, Gauthier J, Spiegelman D, Noreau A, Yang Y, Pellerin S, Dobrzeniecka S, Côté M, Perreault-Linck E, Carmant L, D'Anjou G, Fombonne E, Addington AM, Rapoport JL, Delisi LE, Krebs MO, Mouaffak F, Joober R, Mottron L, Drapeau P, Marineau C, Lafrenière RG, Lacaille JC, Rouleau GA, and Michaud JL. Mutations in SYNGAP1 in Autosomal Non-Syndromic Mental Retardation, *N Engl J Med*. 2009 Feb 5;360(6):599-605. (IF 52,589) Article
112. Hazane F, Krebs M-O, Jay TM, Le Pen G. Behavioral perturbations after prenatal neurogenesis disturbance in female rat. *Neurotoxicity Research* 2009, 15 : 311-320 (IF 5,234).
113. Kebir O, Mouaffak F, Chayet M, Leroy S, Tordjman S, Amado I, Krebs MO. Semantic but not phonological verbal fluency associated with BDNF Val66Met polymorphism in schizophrenia. *Am J Med Genet B Neuropsychiatr Genet*. 2009; 150B(3): 441-2.

114. **Krebs MO, Bellon A, Mainguy G, Jay TM, Frieling H. One-carbon metabolism and schizophrenia: current challenges and future directions. *Trends Mol Med.* 2009 Dec;15(12):562-70.**
115. Kruse MS, Premont J, Krebs MO, Jay T. Interaction of Dopamine D1 with NMDA NR1 receptors in rat prefrontal cortex.. *European Neuropsychopharmacol.* 2009 Apr;19(4):296-304 (IF 4,43) Article
116. Laroche F, Ramoz N, Leroy S, Fortin C, Rousselot-Paillet B, Philippe A, Colleaux L, Bresson JL, Mogenet A, Golse B, Mouren-Simeoni MC, Gorwood P, Galli T, Simonneau M, Krebs MO, Robel L. Polymorphisms of coding trinucleotide repeats of homeogenes in neurodevelopmental psychiatric disorders. *Psychiatr Genet.* 2008 Dec;18(6):295-301.
117. Mechri A, Bourdel MC, Slama H, Gourion D, Gaha L, Krebs MO. Neurological soft signs in patients with schizophrenia and their unaffected siblings: frequency and correlates in two ethnic and socioeconomic distinct populations. *Eur Arch Psychiatry Clin Neurosci.* 2009; 259 (4):218-26.
118. Mouaffak F, Gaillard R, Burgess E, Zaki H, Olié JP, Krebs MO. Clozapine-induced serositis: review of its clinical features, pathophysiology and management strategies *Clin Neuropharmacol.* 2009 Jul-Aug;32(4):219-23.
119. Picard HJ, Amado I, Bourdel MC, Landgraf S, Olié JP, Krebs MO. Correlates between neurological soft signs and saccadic parameters in schizophrenia. *Prog Neuropsychopharmacol Biol Psychiatry.* 2009 Jun 15;33(4):676-681.
- ◆ **2008**
120. Amado, I., Landgraf, S.; Bourdel, M.-C.; Leonardi, S.; Krebs MO. Predictive saccades are impaired in biological non psychotic siblings of patients with schizophrenia” *J Psych Neurosci.* 2008, 33 :17-22. (IF 3,662)
121. Fatjó-Vilas, M, Gourion, D, Campanera S, Mouaffak F, Levy-Rueff M, Navarro E, Chayet M, Miret S., Krebs MO, Fañanas L. New evidences of gene and environment interactions affecting prenatal neurodevelopment in schizophrenia-spectrum disorders: a family dermatoglyphic study. *Schizophrenia Res.* 2008 , 103 : 209-17. (IF 4,24)
122. Grillon ML, Johnson MK, Krebs MO, Huron C. Comparing effects of perceptual and reflective repetition on subjective experience during later recognition memory. *Conscious Cogn.* 2008,17:753-64..
123. **Hoareau C, Borrell V, Soriano E, Krebs MO, Prochiantz A, Allinquant B. APP cytoplasmic domain antagonizes reelin neurite outgrowth inhibition of hippocampal neurons. *Neurobiol Aging.* 2008, 29: 542-53. (IF 5,607)**
124. Kebir O, Mouaffak F, Chayet M, Leroy S, Tordjman S, Amado I, Krebs MO Semantic but not phonological verbal fluency associated with BDNF Val66Met polymorphism in schizophrenia *Am J Med Genet B Neuropsychiatr Genet.* 2008 Jun 5. [Epub ahead of print] (IF 4,224)
125. Landgraf S, Amado I, Bourdel MC, Leonardi S, Krebs MO. Memory-guided saccade abnormalities in schizophrenic patients and their healthy, full biological siblings. *Psychol Medicine.* 2008, 38:861-70 (IF 4,212)
126. Mallet L, Polosan M, Jaafari N, Baup N, Welter ML, Fontaine D, Tezenas Du Montcel S, Yelnik J, Chéreau I, Arbus C, Raoul S, Aouizerate B, Damier P, Chabardès S, Czernecki V, Ardouin C, Krebs MO, Bardinet E, Chaynes P, Burbaud P, Cornu P, Derost P, Bougerol T, Bataille B, Mattei V, Dormont D, Devaux B, Vérin M, Houeto JL, Pollak P, Benabid AL, Agid Y, Krack P, Millet B and Pelissolo A, for the French “Stimulation dans le Trouble Obsessionnel Compulsif (STOC)” Study Group*; **Subthalamic Nucleus Stimulation in Severe Obsessive Compulsive Disorder, *New Eng J Med*, 2008 Nov 13;359(20):2121-34 (IF 52,589)**
127. Picard H, Amado I, Mouchet-Mages S, Olié JP, Krebs MO. The role of the cerebellum in schizophrenia: an update of clinical, cognitive and functional evidence *Schizophrenia Bull* 2008, 34: 155-72 (IF 5,843)
- ◆ **2007**
128. Ballon N., Roy C., Leroy S., Bourdel MC, Olié JP, Charles-Nicolas A., Krebs MO, Poirier MF Polymorphisms TaqI A of the DRD2, Ball of the DRD3, exon III repeat of the DRD4, and 3' UTR VNTR of the DAT: association with childhood ADHD in male African-Caribbean cocaine dependents? *Am J Med Genetics B Neuropsychiatr Gent.* 2007, 144:1034-41. (IF 4,224)
129. Léna I, Chessel A, Le Pen G, Krebs MO, Garcia R : Alterations in prefrontal glutamatergic and noradrenergic systems following MK-801 administration in rats prenatally exposed to methylazoxymethanol at gestational day 17. *Psychopharmacology*, 2007 ; 192:373-383. (IF 3,561)
130. Mouaffak F., Gallarda T., Baup N., Olié JP., Krebs MO. **Gender Identity Disorders and Bipolar Disorder Associated With the Ring Y Chromosome. Letters to the editor. *Am J Psychiatry*, 2007; 164(7):1122-3. (IF 9,127)**
131. Mouchet-Mages S, Cachia A, Canceil O., Rodrigo S, Willard D, Oppenheim C, Meder JF, Martinot JL, Krebs MO : Sensory dysfunction is correlated to cerebellar volume reduction in early schizophrenia. *Schizophrenia Res* 2007;91:266-269. (IF 4,24)
132. Sonnier L*, Le Pen G**, Hartmann A, Bizot JC, Trovero F, Krebs MO, Prochiantz A : Progressive Loss of Dopaminergic Neurons in the Ventral Midbrain of adult mice heterozygote for Engrailed1. *J. Neuroscience* 2007, 27:1063-71 (IF 7,49)

* contributed equally to the work

◆ 2006

133. Ballon N, Leroy S, Roy C, Bourdel MC, Charles-Nicolas A, Krebs MO, Poirier MF. (AAT)n repeat in the cannabinoid receptor gene (CNR1): association with cocaine addiction in an African-Caribbean populations *Pharmacogenomics J*, 2006, 6: 126-130. (IF 3,371)
134. Baylé FJ, Daban C, Amado-Boccaro I, Willard D, Bourdel MC, Olié JP, Krebs MO. Attention in impulsivity : high alternance and impaired attentional fixity. *Cognit Neuropsychiatry*, 2006, 11 : 452-64
135. Dervaux A, Bayle FJ, Laqueille X, Bourdel MC, Leborgne M, Olié JP, Krebs MO. Validity of the CAGE questionnaire in schizophrenic patients with alcohol abuse and dependence. *Schizophr. Res*, 2006, 81: 151-155. (IF 4,240)
136. Hoareau C, Hazane F, Le Pen G, Krebs MO. Postnatal effect of embryonic neurogenesis disturbance on reelin level in organotypic cultures of rat hippocampus *Brain Res* 2006; 1097(1):43-51. (IF 2,218)
137. Krebs MO, Kazes M, Olié JP, Loo H, Akiskal K, Akiskal H. The French version of the validated short TEMPS-A: The temperament evaluation of Memphis, Pisa, Paris and San Diego. *J Affect Disord*. 2006 Dec;96(3):271-3. (IF 3,144)
138. Le Pen G., Gourevitch R., Hazane F., Hoareau C., Jay T.M., Krebs MO. Peri-pubertal maturation after developmental disturbance: a model for psychosis onset in the rat. *Neuroscience*, 2006 143(2):395-405. (IF 3,352)
139. Ouali A., Krebs M.O., Ramdane Cherif, A : Data mining based Bayesian networks for best classification. *Computational Statistics & Data Analysis*, 2006, 51 (2) 15, 1278-1292.
140. Sengupta S, Xiong L, Fathalli F, Benkelfat C, Tabbane K, Danics Z, Labelle A, Lal S, Krebs MO, Rouleau G, Joober R. Association study of the trinucleotide repeat polymorphism within SMARCA2 and schizophrenia. *BMC Genet*. 2006;7(1):34 (IF 1,582)

◆ Avant 2006

141. Amado I, Galinowski A, Daban C, Ramdane-Cherif Z, Poirier E, Bourdel M, Poirier MF, Krebs MO. Effects of lithium on saccadic eye movements in healthy subjects in a ten-day double-blind placebo-controlled cross-over pilot study. *Pharmacopsychiatry*, 2005, 38: 321-325. (IF 3,234)
142. Daban C, Amado I, Bourdel MC, Loo H, Olié JP, Poirier MF, Krebs MO. Cognitive dysfunctions in medicated and unmedicated patients with recent-onset schizophrenia. *J. Psychiatr. Res*, 2005, 39: 391-398. (IF 3,710)
143. Delorme R, Betancur C, Wagner M, Krebs MO, Gorwood P, Pearl P, Nygren G, Durand CM, Buhtz F, Pickering P, Melke J, Ruhrmann S, Anckarsater H, Chabane N, Kipman A, Reck C, Millet B, Roy I, Mouren-Simeoni MC, Maier W, Rastam M, Gillberg C, Leboyer M, Bourgeron T. Support for the association between the rare functional variant I425V of the serotonin transporter gene and susceptibility to obsessive compulsive disorder. *Mol. Psychiatry*, 2005, 10: 1059-1061. (IF 10,900)
144. Delorme R, Golmard JL, Chabane N, Millet B, Krebs MO, Mouren-Simeoni MC, Leboyer M. Admixture analysis of age at onset in obsessive-compulsive disorder. *Psychol. Med.*, 2005, 35: 237-243. (IF 4,212)
145. Goldberger C, Gourion D, Leroy S, Schürhoff F, Bourdel MC, Leboyer M, Krebs MO. Population-based and family-based association study of 5'UTR polymorphism of the reelin gene and schizophrenia. *Am J Med Genet - Neuropsychiatry Genet.*, 2005, 137: 51-55. (IF 4,224)
146. Gourion D, Goldberger C, Leroy S, Bourdel MC, Olié JP, Krebs MO. Age at onset of schizophrenia: interaction between brain-derived neurotrophic factor and dopamine D3 receptor gene variantS *Neuroreport*, 2005, 16: 1407-1410. (IF 2.163)
147. Krebs MO, Goldberger C, Dervaux A. Cannabis use and schizophrenia. *Am. J. Psychiatry*, 2005, 162: 401-402. (IF 9,127)
148. Ouali A, Ramdane-Cherif Z, Levy N and Krebs MO. ~Phenotype Analysis in Schizophrenia using Neural Networks The International Association of Science and Technology for development (IASTED) on biomedical engineering ~biomed 2005, Innsbruck, Austria, February 16-18, 2005.
149. Bah J, Quach H, Ebstein RP, Segman RH, Melke J, Jamain S, Rietschel M, Modai I, Kanas K, Kami O, Lerer B, Gourion D, Krebs MO, Etain B, Schurhoff F, Szoke A, Leboyer M, Bourgeron T. Maternal transmission disequilibrium of the glutamate receptor GRIK2 in schizophrenia. *Neuroreport*, 2004, 15:1987-1991 (IF 2.163)
150. Daban C, Krebs MO, Bourdel MC, Willard D, Loo H, Olié JP, Poirier MF, Amado I. Effects of atypical neuroleptics on alertness and visual orienting in stabilized schizophrenic patients: a preliminary study. *Int J Neuropsychopharmacol*, 2004, 7:255-63. (IF 4,895)
151. Delorme R, Krebs MO, Chabane N, Roy I, Millet B, Mouren-Simeoni MC, Maier W, Bourgeron T, Leboyer M. Frequency and transmission of glutamate receptors GRIK2 and GRIK3 polymorphisms in patients with obsessive compulsive disorder; *Neuroreport*, 2004, 15: 699-702. (IF 2.163)
152. Dervaux A, Baylé FJ, Laqueille X, Bourdel MC, Leborgne MH, Olié JP, Krebs MO. Nicotine use in schizophrenia and disinhibition. *Psychiatry Res* 128 (2004); 229-234. (IF 2,298)
153. Dervaux A, Laqueille X, Krebs MO. Cannabis and vulnerability for psychosis *Br J Psychiatry*, 2004 , 185, 352. (IF 5,446)
154. Gourevitch R, Rocher C, Le Pen G, Krebs MO, Jay TM. Working memory deficits in adult rats after prenatal disruption of neurogenesis *Behav Pharmacol*, 2004, 15:287-292. (IF 2,389)
155. Gourion D, Goldberger C, Bourdel MC, Bayle FJ, Loo H, Krebs MO. Minor physical anomalies in patients with schizophrenia and their parents: prevalence and pattern of craniofacial abnormalities *Psychiatry Res*, 2004, 125:21-8. (IF 2,298)

156. Gourion D, Goldberger C, Olié JP, Loo H, Krebs MO. Neurological and morphological anomalies and the genetic liability to schizophrenia: a composite phenotype. *Schizophr Res*, 2004, 67:23-31. (IF 4,240)
157. Gourion D, Leroy S, Bourdel MC, Goldberger C, Poirier MF, Olié JP, Krebs MO. Cerebellum development and schizophrenia: an association study of the human homeogene Engrailed 2. *Psychiatry Res*, 2004, 126:93-8. (IF 2,298)
158. Millet B, Kochman F, Gallarda T, Krebs MO, Demonfaucon F, Barrot I, Bourdel MC, Olie JP, Loo H, Hantouche EG. Phenomenological and comorbid features associated in obsessive-compulsive disorder: influence of age of onset. *J Affect Disord*, 2004, 79:241-6. (IF 3,144)
159. Ouali A, Ramdane-cherif A, Levy N, Krebs MO. Knowledge Discovery in Schizophrenia using Association RuleS ISCA 17th International Conference on Computer Applications in Industry and Engineering (CAINE-2004), San Francisco, California, USA, November 17-19, 2004
160. Ramdane Cherif Z, Naït-Ali A, Motsch JF, Krebs MO. An autoregressive model applied to eye tremor movement, clinical application in schizophrenia. *J Med Systems*, 2004, 28:489-495.(IF 0,450)
161. Ramdane Cherif Z, Naït-Ali A, Motsch JF, Krebs MO. Performance of a computer system for recording and analysing eye gaze position using an infrared light device. *J Clin Monit Comput*, 2004, 18:39-44.
162. Bayle FJ, Leroy S, Gourion D, Millet B, Olie JP, Poirier MF, Krebs MO. 5HTTLPR polymorphism in schizophrenic patients: further support for association with violent suicide attempts *Am J Med Genet*, 2003, 119B:13-7. (IF 4,224)
163. Baylé FJ, Krebs MO, Martin C, Bouvard MP, Wender P. [French version of Wender Utah rating scale (WURS)] *Can J Psychiatry*. 2003 Mar;48(2):132..
164. Daban C, Amado I, Bayle F, Gut A, Willard D, Bourdel MC, Loo H, Olie JP, Millet B, Krebs MO, Poirier MF. Disorganization syndrome is correlated to working memory deficits in unmedicated schizophrenic patients with recent onset schizophrenia. *Schizophr Res*, 2003, 61:323-4. (IF 4,240)
165. Krebs MO, Olie JP. Tardive dystonia induced by risperidone. *Can J Psychiatry*. 1999 Jun;44(5):507-8.
166. Gourion D, Goldberger C, Bourdel MC, Bayle FJ, Millet B, Olie JP, Krebs MO. Neurological soft-signs and minor physical anomalies in schizophrenia: differential transmission within families *Schizophr Res* 2003, 63 :181-7. (IF 4,240)
167. Millet B, Chabane N, Delorme R, Leboyer M, Leroy S, Poirier MF, Bourdel MC, Mouren-Simeoni MC, Rouillon F, Loo H, Krebs MO. Association between the dopamine receptor D4 (DRD4) gene and obsessive-compulsive disorder. *Am J Med Genet*. 2003, 116B:55-9. (IF 4,224)
168. Ouali A, Ramdane-cherif Z, Ramdane-cherif A, Levy N, Krebs MO. Agent Paradigm in Clinical Large-Scale Data Mining Environment. *Second IEEE International Conference on Cognitive Informatics*, London, United Kingdom 18-20 August 2003 ICCI2003.
169. Schurhoff F, Krebs MO, Szoke A, Loze JY, Goldberger C, Quignon V, Tignol J, Rouillon F, Laplanche JL, Leboyer M. Apolipoprotein E in schizophrenia: a French association study and meta-analysis *Am J Med Genet*, 2003, 119B:18-23. (IF 4,224)
- 170. Krebs MO, Betancur C, Leroy S, Bourdel MC, Gillberg C, Leboyer M : Absence of association between a polymorphic GGC repeat in the 5' untranslated region of the reelin gene and autism : *Mol Psychiatry*, 2002, 7, 801-804 (IF : 6,25)**
171. Dervaux A, Bayle FJ and Krebs MO: Substance misuse in schizophrenic patients: similarities and differences between UK and France. *Brit J Psychiatry*, 2002, 180: 381. (IF : 4,143)
172. Krebs MO, Gut-Fayand A, Amado I, Daban C, Bourdel MC, Poirier MF and Berthoz A: Impairment of predictive saccades in schizophrenia *Neuroreport* 2001, 12, 465-9 (IF : 2,374)
- 173. Dervaux A, Bayle FJ, Laqueille , Bourdel MC, LeBorgne MH, Olié JP, Krebs MO Is substance abuse in schizophrenia related to impulsivity, sensation seeking or anhedonia ? *Am J Psychiatry*, 2001, 158, 492-4 (IF : 6,913)**
174. Leroy S, Griffon N, Bourdel MC, Loo H, Olié JP, Poirier MF and Krebs MO: Schizophrenia and the Cannabinoid receptor type 1 (CB1) : Association study using a single base polymorphism in the coding exon 1. *Am J Med Genetics* 2001 ; 105 : 749-752. (IF : 2,378)
175. Gut-Fayand A, Dervaux A, Olie JP, Loo H, Poirier MF, Krebs MO: Substance abuse and suicidality in schizophrenia : a common risk factor linked to impulsivity *Psychiatry Res* , 2001, 102 , 65-72 (IF : 1,775)
176. Bayle FJ, Krebs MO, Epelbaum C, Levy D, Hardy P : Clinical features of panic attacks in schizophrenia. *Eur Psychiatry* 2001 ; 16 : 1-5. (IF : 1,072)
- 177. Krebs MO, Guillin O., Bourdel MC., Schwartz JC., Olié JP., Poirier MF., Sokoloff P. BDNF gene variants association with age at onset and therapeutic response in schizophrenia. *Mol Psychiatry*, 2000 , 5, 558-62. (IF : 6,25)**
178. Krebs MO, Gut-Fayand A., Bourdel MC, Dischamp J., Olié JP. Validation an factorial structure of a standardized neurological examination assessing neurological soft-signs in schizophrenia. *Schizophrenia Res.*, 2000, 45, 245-60. (IF : 3,567)
- 179. Ito C., Krebs MO, Olié JP., Loo H., Poirier MF., Lannfelt L., Schwartz JC and Arrang JM. Histamine H2 receptor gene variants : lack of association with schizophrenia. *Mol Psychiatry*, 2000, 5, 159-64. (IF : 6,25)**
180. Duaux E, Krebs MO, Loo H, Poirier MF. Genetic vulnerability to drug abuse. *Eur Psychiatry*. 2000 Mar;15(2):109-14.
181. Krebs MO and Olie JP. Tardive dystonia induced by risperidone. *Can J Psychiatry* . 1999;44 :507-8. (IF : 1,624)

182. **Krebs MO, Sautel F, Bourdel MC, Sokoloff P, Schwartz JC, Olié JP, Lèo H, Poirier MF.** Dopamine D3 receptor gene variants and substance abuse in schizophrenia. *Mol Psychiatry*, 1998 ; 3 : 337-341. (IF : 6,25)
183. **Chabriat H, Tournier-Lasserre, Vahedi K, Nibbio A, Joutel A, Iba-Zizen MT, Mas JL, Krebs MO, Ducrocq X, Levasseur M, Julien J, Derouesné C and Bousser MG** The clinical spectrum of CADASIL (cerebral autosomal dominant arteriopathy with subcortical infarcts and leucoencephalopathy). *Lancet*, 1995, 346 : 934-939 (IF : 13, 251)
184. **Krebs MO, Gauchy C., Desban M., Glowinski J. and Kemel M.L., 1994 :** Roles of dynorphin and GABA in the NMDA-induced inhibitory regulation of DA release in striosome-and matrix-enriched areas of the rat striatum *The Journal of Neuroscience* 14, 2435-2443 (IF : 8,178)
185. **Krebs MO, Kemel M.L., Gauchy C., Desban M. and Glowinski J., 1993:** Local GABAergic regulation of the NMDA-evoked release of DA is more important in striosomes than in matrix of the rat striatum. *Neuroscience*, 57, 249-260 (IF : 3, 219)
186. **Krebs MO, Kemel M.L., Gauchy C., Desban M. and Glowinski J., 1993 :** Does bicuculline antagonizes NMDA receptor? further evidence in the rat striatum. *Brain Res.*, 634, 345-348. (IF : 2,489)
187. **Krebs MO, Desce J.M., Kemel M.L., Gauchy C., Godeheu G., Cheramy A. and Glowinski J. 1991:** Glutamatergic control of dopamine release in the rat striatum: evidence for presynaptic N-Methyl-D-Aspartate receptors on dopaminergic nerve terminals. *Journal of Neurochemistry*, 56, 81-85. (IF : 4, 834)
188. **Krebs MO, Trovero F., Desban M., Gauchy C., Glowinski J. and Kemel M.L., 1991:** Distinct presynaptic regulation of dopamine release through NMDA receptors in striosome- and matrix-enriched areas of the rat striatum. *The Journal of Neuroscience*, 11, 1256-1262. (IF : 8,178)
189. **Gauchy C., Desban M., Krebs MO, Glowinski J. and Kemel M.L., 1991:** Role of dynorphin-containing neurons in the presynaptic inhibitory control of the acetylcholine-evoked release of dopamine in the striosomes and the matrix of the cat caudate nucleus. *Neuroscience*, 41, 449-458. (IF : 3, 219)
190. **Krebs MO, Kemel M.L., Gauchy C., Desban M. and Glowinski J. 1989:** Glycine potentiates the NMDA-induced release of dopamine through a strychnine-insensitive site in the rat striatum. *Eur J Pharmacology*. 166, 567-570. (IF : 2,164)
191. **Warot D.; Krebs MO; Bensimon G.; Payan C.; Danjou P.; Lacomblez L. and Puech.A.J. 1988:** Dose-effect study of levomepromazine on psychomotor and memory tasks in healthy volunteers. *Human Psychopharmacology*, 3, 127-132. (IF : 0,968)